Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 3NET 2

Conditions

Neuroendocrine Tumors 69Pheochromocytoma 8Gastro-enteropancreatic neuroendocrine tumor 8Carcinoma, Neuroendocrine 8Paraganglioma 7Carcinoid Tumor 7Adenoma, Islet Cell 7Sarcoma 6Thyroid Neoplasms 5Pancreatic Neoplasms 5Neoplasms 5Melanoma 5Breast Neoplasms 5Prostatic Neoplasms 4Ovarian Neoplasms 4Neuroblastoma 4Neoplasm Metastasis 4Mesothelioma 4Carcinoma, Merkel Cell 4Carcinoma 4Stomach Neoplasms 3Neuroectodermal Tumors, Primitive 3Meningioma 3Liver Neoplasms 3Gallbladder Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Central Nervous System Neoplasms 3Carcinoma, Non-Small-Cell Lung 3

Interventions

Random Allocation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Serotonin Syndrome × NET × 90 days × Clear all
NCT07087054 2026-04-30

CAREFNDR

Crinetics Pharmaceuticals Inc.

Phase 3 Recruiting
141 enrolled
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT05361668 2026-03-19

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Crinetics Pharmaceuticals Inc.

Phase 2 Completed
36 enrolled 19 charts
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡